Brief: Northwest Biotherapeutics said Nasdaq accepts NW Bio Remediation Plan
06/09/2016 13:56
Sept 6 (Reuters) - Northwest Biotherapeutics Inc NWBO.O
* Nasdaq accepts NW Bio Remediation Plan for shares and
warrants previously issued to Cognate Bioservices
* Nasdaq settlement does not affect other obligations of
company to cognate, including for existing unpaid invoices
* Cognate will return and co will cancel a total of 8.8
million shares
* Warrants held by Cognate will be reduced by 2.6 million
Source text for Eikon: ID:nPn4dBBJka
Further company coverage: NWBO.O
((Bangalore.newsroom@thomsonreuters.com;))
Recent news on Northwest Biotherapeutics
See all newsBrief: Northwest Biotherapeutics And The UK National Health Service Blood And Transplant Announce Collaboration To Support Dcvax®-L Production
Brief: Northwest Biotherapeutics Provides Update On Final Preparations For Marketing Authorization Application
Brief: Northwest Biotherapeutics Provides Update On Near Term Plans For Submission Of Marketing Authorization Application
Brief: Northwest Biotherapeutics And Advent Bioservices Announce Receipt Of License For Commercial Manufacturing At Sawston, U.K. Facility
Brief: Northwest Biotherapeutics Announces That It Has No Banking Relationship With SVB